#China #Beijing #cancer therapy #Jacobio Pharma #glecirasib

Jacobio Pharma Reports Strong Growth and Breakthroughs in Interim Results for 2025

Jacobio Pharma Announces 2025 Interim Results

On August 29, 2025, Jacobio Pharma (1167.HK) released its interim financial results for the first half of the year, marking a noteworthy period of growth and pivotal advancements in cancer treatment. The company reported a revenue of RMB 45.7 million, a remarkable increase of 100% compared to the same timeframe in 2024. Notably, the research and development expenses during this period reached RMB 93.2 million, reflecting the company’s commitment to innovation.

Financial Performance Overview

The half-yearly financial report highlighted a net loss of RMB 59 million, which shows a significant improvement, narrowing by 65.1% relative to the first half of 2024. This reduction in loss underscores the efficient management of resources and the fruitful execution of their strategic plans. As of June 30, 2025, Jacobio maintained robust cash and bank balances totaling RMB 1.07 billion along with RMB 270 million in bank credit available, ensuring stable liquidity for continuous investment in research and development activities.

Strategic Milestones Reached

Dr. Yinxiang Wang, the Chairman and CEO of Jacobio Pharma, expressed, "In the first half of 2025, we reached an important milestone with the approval and launch of Glecirasib in China." This approval is particularly significant as it reflects the company's progress in providing innovative therapies to patients. Dr. Wang also emphasized the financial relief obtained through collaborations with business partners, enabling Jacobio to redirect resources toward advancing its pan-KRAS inhibitor and antibody-drug conjugate (ADC) pipeline.

Accelerated Progress in Core Programs

1. JAB-23E73 (pan-KRAS Inhibitor)

Jacobio's phase I trials for its pan-KRAS inhibitor, JAB-23E73, are currently underway in both China and the U.S. Initial findings have indicated a favorable safety profile with low incidences of skin toxicity and no serious liver toxicity reported thus far. Moreover, several partial responses have been recorded amongst trial participants. The preclinical data is anticipated to be presented at the upcoming AACR-NCI-EORTC International Conference in October 2025, with phase I trial results expected in the first half of 2026.

2. JAB-BX600 (First-in-Class EGFR-KRAS G12Di ADC)

This candidate leverages a highly potent KRAS G12D inhibitor as its payload. It possesses picomolar-level activity, significantly outperforming traditional oral small molecules. The JAB-BX600 demonstrates a unique ability to achieve tumor drug concentrations at levels 1,000 times higher than those found in plasma, providing a much broader therapeutic window. The synergistic effects of the KRAS G12D inhibitor and EGFR antibody bolster its anti-tumor efficacy, with IND submission planned for the second half of 2026.

3. Glecirasib (JAB-21822, KRAS G12C Inhibitor)

Glecirasib, which received approval from China's NMPA in May 2025 for treating patients with ≥2L KRAS G12C mutant non-small cell lung cancer (NSCLC), is successfully launched in China. This success resulted in a milestone payment of RMB 50 million, in addition to the upfront payment of RMB 200 million received in 2024. The data from the second-line NSCLC dataset has also been published in Nature Medicine, a high-impact scientific journal, showcasing the credibility of the results.

4. Sitneprotafib (JAB-3312, SHP2 Inhibitor)

Currently, a phase III registration trial is being conducted in China for Sitneprotafib when paired with Glecirasib as a first-line treatment for NSCLC. Translational research outcomes demonstrating substantial synergy with Glecirasib have been published in Clinical Cancer Research.